Zoom Logo

Cardiology and Covid 19 Vaccinations - Shared screen with speaker view
Wil Harrison
15:00
Can you guys hear me?
Dr Pauline Horrill Te Awakairangi Health Network
48:30
what about PPV and risk? seems similar to screening healthy people.
Assoc Prof Helen Petousis-Harris
48:42
12-17 year trial data safety and efficacy https://www.nejm.org/doi/full/10.1056/NEJMoa2109522
Alia
54:07
do trops
Dr Pauline Horrill Te Awakairangi Health Network
58:05
is point 6 asymptomatic lead to long term?
Mei Ling
01:09:34
If Wiremu had myocarditis after the 1st does of vaccine then should he get the second dose of vaccine if there is still community transmission of COVID?
Vanisi Prescott
01:17:30
Could you please clarify if it's been confirmed we can use different vaccines? So if we have had 1 dose of pfizer can we top up with another vaccine such as Astrazeneca?? and will that provide good coverage??
Alia
01:17:41
do cxr
Assoc Prof Helen Petousis-Harris
01:19:13
To clarify my response re mixed schedule - looking good from perspective of immunity but lack of evidence for any change in myocarditis/peri risk yet, await data.
Vanisi Prescott
01:20:35
Great thank you 😁
Dr Pauline Horrill Te Awakairangi Health Network
01:40:38
do we think we missed the point that responding to epidemics is not a scientific response but a social, cultural, treaty base response so need different people engaged around table
CarolineTucker
01:51:03
Great presentation Thanks very much!
Elle Dagley
01:51:15
Thanks for a great presentation